Stabilisierte Antikörperhaltige Flüssige Formulierungen
Anmelder: CHUGAI SEIYAKU KABUSHIKI KAISHA 🇯🇵
Details
- Veröffentlichungs-Nr.
- EP4755374
- Anmeldetag
- 20. Januar 2011
- Veröffentlichung
- 10. Juni 2026
- Rechtsraum
- EP
Abstract
An objective of the present invention is to provide stable antibody-containing formulations which are suitable for subcutaneous administration and in which aggregation formation is suppressed during long-term storage.The present inventors discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid as a counter ion species in histidine buffer or tris(hydroxymethyl)aminomethane, specifically by using histidine-aspartate buffer or histidine-glutamate buffer, or tris(hydroxymethyl)aminomethane-aspartate or tris(hydroxymethyl)aminomethane-glutamate as a buffer. The present inventors also discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid, as a counter ion species to a basic amino acid such as arginine, specifically by using arginine-aspartate or arginine-glutamate.
Anmelder
- Firma
- CHUGAI SEIYAKU KABUSHIKI KAISHA
- Land
- 🇯🇵 Japan
Chugai Pharmaceutical Co., Ltd. ist ein japanisches Pharmaunternehmen mit Sitz in Tokio, das insbesondere Biopharmazeutika entwickelt und mehrheitlich zur Roche-Gruppe gehört.
1.167 Patente in unserer Datenbank